Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. (apre una nuova finestra)

Antun AG, Gleason S, Arellano M, Langston AA, McLemore ML, Gaddh M, el Rassi F, Bernal-Mizrachi L, Galipeau J, Heffner LT Jr, Winton EF, Khoury HJ.

Fonte‎: Cancer 2013;119(21):3784-7.

Indicizzato‎: PubMed 23921838

DOI‎: 10.1002/cncr.28253

https://www.ncbi.nlm.nih.gov/pubmed/23921838 (apre una nuova finestra)

Low dose bolus aminocaproic acid: an alternative to platelet transfusion in thrombocytopenia? (apre una nuova finestra)

Chakrabarti S, Varma S, Singh S, Kumari S

Fonte‎: Eur J Haematol 1998;60(5):313-4.

Indicizzato‎: PubMed 9654162

DOI‎: 10.1111/j.1600-0609.1998.tb01046.x

https://www.ncbi.nlm.nih.gov/pubmed/9654162 (apre una nuova finestra)

The use of antifibrinolytics in pediatric patients with hypoproliferative thrombocytopenia. (apre una nuova finestra)

Delaney M, Matthews DC, Gernsheimer TB

Fonte‎: Pediatr Blood Cancer 2017;64(12):e26641.

Indicizzato‎: PubMed 28544698

DOI‎: 10.1002/pbc.26641

https://www.ncbi.nlm.nih.gov/pubmed/28544698 (apre una nuova finestra)

Preliminary experience with epsilon aminocaproic acid for treatment of intractable upper tract hematuria in children with hematological disorders. (apre una nuova finestra)

Kaye JD, Smith EA, Kirsch AJ, Cerwinka WH, Elmore JM

Fonte‎: J Urol 2010;184(3):1152-7.

Indicizzato‎: PubMed 20650477

DOI‎: 10.1016/j.juro.2010.05.020

https://www.ncbi.nlm.nih.gov/pubmed/20650477 (apre una nuova finestra)

A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. (apre una nuova finestra)

Shpilberg O, Blumenthal R, Sofer O, Katz Y, Chetrit A, Ramot B, Eldor A, Ben-Bassat I.

Fonte‎: Leuk Lymphoma 1995;19(1-2):141-4.

Indicizzato‎: PubMed 8574160

DOI‎: 10.3109/10428199509059668

https://www.ncbi.nlm.nih.gov/pubmed/8574160 (apre una nuova finestra)

Pediatric off-label use of recombinant factor VIIa. (apre una nuova finestra)

Alten JA, Benner K, Green K, Toole B, Tofil NM, Winkler MK.

Fonte‎: Pediatrics 2009;123(3):1066-72.

Indicizzato‎: PubMed 19255041

DOI‎: 10.1542/peds.2008-1685

https://www.ncbi.nlm.nih.gov/pubmed/19255041 (apre una nuova finestra)

Recombinant activated factor VII usage in life threatening hemorrhage: a pediatric experience. (apre una nuova finestra)

Bhat S, Yadav SP, Anjan M, Dinand V, Sachdeva A.

Fonte‎: Indian J Pediatr 2011;78(8):961-8.

Indicizzato‎: PubMed 21328080

DOI‎: 10.1007/s12098-011-0364-6

https://www.ncbi.nlm.nih.gov/pubmed/21328080 (apre una nuova finestra)

Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated Factor VII. (apre una nuova finestra)

Brenner B, Hoffman R, Balashov D, Shutluko E, Čulić SD, Nizamoutdinova E.

Fonte‎: Clin Appl Thromb Hemost 2005;11(4):401-10.

Indicizzato‎: PubMed 16244765

https://www.ncbi.nlm.nih.gov/pubmed/16244765 (apre una nuova finestra)

Safety and efficacy of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate use and trial data supporting US label. (apre una nuova finestra)

Croteau SE, Nakar C, Neufeld EJ, Shapiro A, Cooper DL

Fonte‎: Pediatr Blood Cancer 2016;63(10):1822-8.

Indicizzato‎: PubMed 27232114

DOI‎: 10.1002/pbc.26082

https://www.ncbi.nlm.nih.gov/pubmed/27232114 (apre una nuova finestra)

Use of recombinant factor VIIa prior to lumbar puncture in pediatric patients with acute leukemia. (apre una nuova finestra)

Das P, Carcao M, Hitzler J

Fonte‎: Pediatr Blood Cancer 2006;47(2):206-9.

Indicizzato‎: PubMed 16007583

DOI‎: 10.1002/pbc.20467

https://www.ncbi.nlm.nih.gov/pubmed/16007583 (apre una nuova finestra)

A comprehensive review of rFVIIa use in a tertiary care pediatric center. (apre una nuova finestra)

Heller M, Lau W, Pazmino-Canizares J, Brandão LR, Carcao M

Fonte‎: Pediatr Blood Cancer 2008;50(5):1013-7.

Indicizzato‎: PubMed 17960639

DOI‎: 10.1002/pbc.21375

https://www.ncbi.nlm.nih.gov/pubmed/17960639 (apre una nuova finestra)

Recombinant activated factor VII for severe gastrointestinal bleeding after chemotherapy in an infant with acute megakaryoblastic leukemia. (apre una nuova finestra)

Kurekci AE, Atay AA, Okutan V, Yavuz ST, Ozcan O

Fonte‎: Blood Coagul Fibrinolysis 2005;16(2):145-7.

Indicizzato‎: PubMed 15741803

DOI‎: 10.1097/01.mbc.0000161569.66764.70

https://www.ncbi.nlm.nih.gov/pubmed/15741803 (apre una nuova finestra)

Off-label use of recombinant factor VIIa in pediatric patients. (apre una nuova finestra)

McQuilten ZK, Barnes C, Zatta A, Phillips LE; Haemostasis Registry Steering Committee

Fonte‎: Pediatrics 2012;129(6):e1533-40.

Indicizzato‎: PubMed 22641758

DOI‎: 10.1542/peds.2011-2561

https://www.ncbi.nlm.nih.gov/pubmed/22641758 (apre una nuova finestra)

Dosing, efficacy, and safety of recombinant factor VIIa (rFVIIa) in pediatric versus adult patients: the experience of the Hemostasis and Thrombosis Research Society (HTRS) registry (2004-2008). (apre una nuova finestra)

Neufeld EJ, Saxena K, Kessler CM, Cooper DL; HTRS Investigators

Fonte‎: Pediatr Blood Cancer 2013;60(7):1178-83.

Indicizzato‎: PubMed 23335449

DOI‎: 10.1002/pbc.24472

https://www.ncbi.nlm.nih.gov/pubmed/23335449 (apre una nuova finestra)

Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII: report on one case and review of other uses in acute leukemias. (apre una nuova finestra)

Pamuk GE, Taşçi M, Oztürk E, Demir M.

Fonte‎: Med Oncol 2010;27(1):16-9.

Indicizzato‎: PubMed 19137431

DOI‎: 10.1007/s12032-008-9163-y

https://www.ncbi.nlm.nih.gov/pubmed/19137431 (apre una nuova finestra)

Successful treatment of acute lymphoblastic leukemia with l-asparaginase-induced intracranial hemorrhage to activated recombinant factor VIIa in a child. (apre una nuova finestra)

Ucar C, Caliskan U

Fonte‎: Pediatr Hematol Oncol 2006;23(4):339-45.

Indicizzato‎: PubMed 16621776

DOI‎: 10.1080/08880010600631987

https://www.ncbi.nlm.nih.gov/pubmed/16621776 (apre una nuova finestra)

Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder. (apre una nuova finestra)

Yilmaz D, Karapinar B, Balkan C, Akisü M, Kavakli K.

Fonte‎: Pediatr Hematol Oncol 2008;25(4):301-11.

Indicizzato‎: PubMed 18484474

DOI‎: 10.1080/08880010802016904

https://www.ncbi.nlm.nih.gov/pubmed/18484474 (apre una nuova finestra)

The use of DDAVP in children with bleeding disorders. (apre una nuova finestra)

Ben-Ami T, Revel-Vilk S

Fonte‎: Pediatr Blood Cancer 2013;60 Suppl 1:S41-3.

Indicizzato‎: PubMed 23109357

DOI‎: 10.1002/pbc.24335

https://www.ncbi.nlm.nih.gov/pubmed/23109357 (apre una nuova finestra)

Treatment of refractory thrombocytopenic bleeding with 1-desamino-8-D-arginine vasopressin (desmopressin). (apre una nuova finestra)

Kobrinsky NL, Tulloch H

Fonte‎: J Pediatr 1988;112(6):993-6.

Indicizzato‎: PubMed 3373409

DOI‎: 10.1016/s0022-3476(88)80234-8

https://www.ncbi.nlm.nih.gov/pubmed/3373409 (apre una nuova finestra)

The use of Tachosil as hemostatic sealant in nephron sparing surgery for Wilms tumor: preliminary observations. (apre una nuova finestra)

Mele E, Ceccanti S, Schiavetti A, Bosco S, Masselli G, Cozzi DA

Fonte‎: J Pediatr Surg 2013;48(3):689-94.

Indicizzato‎: PubMed 23480936

DOI‎: 10.1016/j.jpedsurg.2013.01.019

https://www.ncbi.nlm.nih.gov/pubmed/23480936 (apre una nuova finestra)